Harnessing New Insights into Human Genetics & Stem Cell Technology to Provide Genetically-Validated Targets for the Sporadic ALS Patient Populations

Time: 8:30 am
day: Day Two


  • Investigating genetically validated targets in ALS patient-derived cells to develop precision therapeutics
  • Examining the emerging role of aberrant splicing in the development of disease
  • Highlighting the need of human model systems to select the right therapeutic candidate molecules